The New Lung Cancer Divide: Rural, Low-Income Young Adults Left Behind
“A sweeping U.S. analysis of 18,595 people aged 18–50 diagnosed with early-onset non–small cell lung cancer (NSCLC) has a blunt message: outcomes hinge not only on tumor biology but on where you live, what you earn, and how fast you receive care. More than half of these young adults—53.4%—were already at Stage IV when doctors first met them, a late presentation that sets survival on a steep downhill path from day one. The work, published October 13, 2025, in JAMA Network Open, reframes lung cancer in the young as a social and systems problem as much as a clinical one.”
American Lung Association Launches Campaign to Educate People Living With Lung Cancer and Lung Disease About Critical Vaccines
“Today, the American Lung Association launched a new campaign aimed at educating the public on the importance of staying up to date on recommended vaccinations for the upcoming respiratory virus season. This guidance is especially critical for the more than 35 million people in the United States living with chronic lung disease and the 235,000 people diagnosed with lung cancer each year, who are at higher risk for severe illness.”
HIV and lung cancer: a single cancer center experience
“Our cohort showed more advanced disease at presentation, younger age at diagnosis, and poor OS despite most patients having undetectable HIV viral loads on antiviral therapy, suggesting a link between well-controlled HIV and aggressive LC that warrants further study.”
USC Nursing research helps lung cancer patients live better, longer
“At the university’s Cancer Survivorship Research Center, nurse scientists are leading innovative studies to help people living with and beyond lung cancer better manage symptoms, maintain treatment, and enhance their quality of life.”
Wait times between lung cancer diagnosis and surgery: national trends, disparities, and impact on long-term survival
“Conclusions: Wait times exceeding 4 weeks between lung cancer diagnosis and surgery for stage I and II NSCLC are increasingly common, particularly among non-Hispanic Black patients, and are associated with worse long-term survival. Reducing time between cancer diagnosis and surgery may represent a therapeutic target to mitigate healthcare disparities.”
Team’s Biosensor Technology May Lead to Breath Test for Lung Cancer
“University of Texas at Dallas researchers have developed biosensor technology that when combined with artificial intelligence (AI) shows promise for detecting lung cancer through breath analysis. The electrochemical biosensor identifies eight volatile organic compounds (VOCs) that are potential biomarkers for thoracic cancers, which include lung and esophageal cancers. AI then analyzes the biochemical characteristics of the compounds to determine whether they are a match to those linked to various thoracic cancers.”
Online Program Increases Lung Cancer Screening Rates
“Key Takeaways: An online program improved lung cancer screening rates. The program offered an online educational video and a tool to weigh risks and benefits. Nearly 25% of patients assigned the program got a CT scan, compared to 17% of patients referred to their doctors.”
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
“ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY®) and third line therapy amivantamab (EGFR-cMET bispecific RYBREVANT®). Combination of ATNM-400 and osimertinib resulted in complete tumor regression in 100% of tumor bearing animals; synergistic mechanism supported by increased ATNM-400 target antigen expression after EGFR inhibition with Osimertinib. Improved progression free survival has been demonstrated clinically with the combination of osimertinib and external beam radiotherapy providing strong rationale for a combination with targeted alpha-therapy. Data validates the multi-tumor potential of ATNM-400 in multiple disease and treatment settings that support several blockbuster drugs.”
Administration of statins is correlated with favourable prognosis in lung cancer patients receiving immune checkpoint inhibitors
“Conclusion: Statin use was significantly correlated with improved prognosis in lung cancer patients receiving ICIs. Statins may enhance ICI efficacy partly through RORA. Due to study limitations, the actual role of statins and their target genes in anti-cancer immunity needs further investigations.”
Sarcomatoid Lung Carcinoma Successfully Treated With Combined Cytotoxic Chemotherapy and Anti-Programmed Death-Ligand 1 (Anti-PD-L1) Antibodies
“Pulmonary sarcomatoid carcinoma is a rare, aggressive subtype of non-small-cell lung cancer with a poor prognosis and no established standard therapy for advanced disease. We report the case of a 68-year-old man with stage IVB pleomorphic carcinoma whose tumor expressed programmed death-ligand 1 (PD-L1) with a tumor proportion score of 25%. The patient received four cycles of first-line therapy combining atezolizumab with carboplatin and paclitaxel. This treatment resulted in a significant partial response, with marked shrinkage of the primary tumor and metastatic lesions. This case suggests that the combination of an anti-PD-L1 antibody and platinum-based chemotherapy is a promising and effective therapeutic strategy for this challenging malignancy.”
Eosinophils as predictive biomarkers in anti-programmed cell death 1 monotherapy for non-small cell lung cancer
“The relationship between eosinophilia and cancer development has recently been investigated. However, the role of eosinophils in tumor immunity, particularly in the context of immune checkpoint inhibitor (ICI) therapy, remains poorly understood.”
